April 26, 2024

Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating Human Immunodeficiency Virus Viral Suppression and Perinatal Outcomes

Key Points

Key points are not available for this paper at this time.

Abstract

Abstract This study describes the largest cohort to date (n = 147) of pregnant patients with human immunodeficiency virus (HIV) on bictegravir (BIC). BIC in pregnancy was associated with high levels of viral suppression and perinatal outcomes similar to those in the published literature. These findings support consideration for the use of BIC in managing HIV during pregnancy.

Bookmark

Cite This Study

Holt et al. (Fri,) studied this question.

synapsesocial.com/papers/68e6d58fb6db643587652ee2 https://doi.org/https://doi.org/10.1093/cid/ciae218

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–20112014 · 394 citations
2Investigation of factors associated with spontaneous preterm birth in pregnant women living with HIV2019 · 34 citations
3Perinatal outcomes in women living with HIV‐1 and receiving antiretroviral therapy—a systematic review and meta‐analysis2021 · 52 citations
4Efficacy and Safety of Bictegravir-Based Regimen in Pregnant Women Living with HIV: A Case Report2022 · 3 citations
5Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial2017 · 395 citations

Bookmark